Singapore, Oct. 8 -- South Korea-based GC Cell, a leader in the cell and gene therapy (CGT) sector within the biopharmaceutical industry, and Israel-based QuantHealth, the global leader in AI-powered clinical trial simulation, have announced a collaboration to bring a simulation-first approach to the design of upcoming clinical trials for GCC2005, GC Cell's investigational CD5-targeted CAR-NK cell therapy for T-cell lymphoma.

The collaboration is intended to advance GCC2005's global clinical development strategy and enhance the design of a planned Phase 2 multi-regional clinical trial (MRCT), using simulation to inform key design decisions before a single patient is enrolled.

Drug development is a costly and laborious process, costing $...